Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers

被引:47
作者
Henderson, EA
Louie, TJ
Ramotar, K
Ledgerwood, D
Hope, KM
Kennedy, A
机构
[1] Univ Calgary, Fac Med, Calgary Reg Hlth Author, Calgary, AB, Canada
[2] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB, Canada
[3] Univ Calgary, Fac Med, Dept Med, Calgary, AB, Canada
[4] Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB, Canada
关键词
D O I
10.1086/501756
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVE: To compare the immunogenicity of hepatitis B vaccine administered via intradermal (ID) versus intramuscular (IM) route. METHODS: Subjects chose either to specify the route of immunization or to undergo random allocation to vaccination by the ID (0.15 mt) or the IM (1.0 mt) route. Yeast-derived recombinant hepatitis B vaccine was given at 0, 30, and 180 days. Hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were measured by microparticle enzyme immunoassay. RESULTS: 763 subjects were enrolled. Baseline screening identified 65 subjects (8%) who were positive for HBsAb or HBcAb. Vaccination was completed by 590 (85%) of 698 enrollees (370 ID, 220 IM). Seroconversion rates (geometric mean titers [GMT]>0 IU/mL HBsAb) for those vaccinated ID were 99% and 96% for screening at 9 months and 1 year post-vaccination, respectively; subjects vaccinated intramuscularly had similar rates of 95% and 9676. Seropositivity rates (GMT greater than or equal to 10 IU/mL HBsAb) showed a similar pattern, with 95%, 92%. and 73% at 9 months and 1 and 2 years, respectively, for those vaccinated ID, and 94%, 93%, and 81% for those having IM vaccination. GMT for HRsAB, was significantly higher for individuals vaccinated IM than for those vaccinated ID (P<.0001). The GMT ratio for the LM and ID routes decreased over time, being 9.3 at 9 months, 7.8 at 1 year, and 5.9 at 2 years. An unanticipated side effect of intradermal vaccination was skin discoloration at injection sites, which persisted for at least 2 years postvaccination. Two thirds (112/166) of respondents reported that they would have selected the ID route despite the discoloration. CONCLUSIONS: Higher-dose ID vaccination (3 vs 1 mu g per injection) uses one sixth of the dose required for standard IM vaccination. It is a cost-effective way to vaccinate populations against hepatitis B virus. but the long-term efficacy of the ID route must still be investigated.
引用
收藏
页码:264 / 269
页数:6
相关论文
共 21 条
[1]  
BARNAS GP, 1988, INFECT CONT HOSP EP, V9, P147
[2]  
BRYAN J, 1989, LOW DOS INTRADERMAL, P133
[3]   COMPARATIVE TRIAL OF LOW-DOSE, INTRADERMAL, RECOMBINANT-DERIVED AND PLASMA-DERIVED HEPATITIS-B VACCINES [J].
BRYAN, JP ;
SJOGREN, M ;
IQBAL, M ;
KHATTAK, AR ;
NABI, S ;
AHMED, A ;
COX, B ;
MORTON, A ;
SHUCK, J ;
MACARTHY, P ;
PERINE, P ;
MALIK, I ;
LEGTERS, LJ .
JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (04) :789-793
[4]   LOW-DOSE INTRADERMAL AND INTRAMUSCULAR VACCINATION AGAINST HEPATITIS-B [J].
BRYAN, JP ;
SJOGREN, MH ;
PERINE, PL ;
LEGTERS, LJ .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (03) :697-707
[5]  
*CDC, 1987, MMWR-MORBID MORTAL W, V36, P353
[6]   INTRADERMAL AND INTRAMUSCULAR ROUTE FOR VACCINATION AGAINST HEPATITIS-B [J].
GONZALEZ, ML ;
USANDIZAGA, M ;
ALOMAR, P ;
SALVA, F ;
MARTIN, F ;
ERROZ, MJ ;
LARDINOIS, R .
VACCINE, 1990, 8 (04) :402-405
[7]   LONG-TERM IMMUNOGENICITY AND EFFICACY OF HEPATITIS-B VACCINE IN HOMOSEXUAL MEN [J].
HADLER, SC ;
FRANCIS, DP ;
MAYNARD, JE ;
THOMPSON, SE ;
JUDSON, FN ;
ECHENBERG, DF ;
OSTROW, DG ;
OMALLEY, PM ;
PENLEY, KA ;
ALTMAN, NL ;
BRAFF, E ;
SHIPMAN, GF ;
COLEMAN, PJ ;
MANDEL, EJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (04) :209-214
[8]   INTRADERMAL HEPATITIS-B VACCINATION IN AN ABBREVIATED SCHEDULE [J].
HALSEY, NA ;
REPPERT, EJ ;
MARGOLIS, HS ;
FRANCIS, DP ;
FIELDS, HA .
VACCINE, 1986, 4 (04) :228-232
[9]   LOW-DOSE INTRADERMAL VACCINATION AGAINST HEPATITIS-B IN MENTALLY-RETARDED PATIENTS [J].
HEIJTINK, RA ;
BREUKERS, AAFM ;
DENHARTIGH, G ;
SCHEPMAN, RWM ;
SCHMITZ, PIM ;
SCHALM, SW ;
MASUREL, N .
VACCINE, 1988, 6 (01) :59-61
[10]  
KRUGMAN S, 1987, YALE J BIOL MED, V60, P333